High-titre convalescent plasma therapy for an immunocompromised patient with systemic lupus erythematosus with protracted SARS-CoV-2 infection.
BMJ Case Rep
; 14(8)2021 Aug 25.
Article
in English
| MEDLINE | ID: covidwho-1373953
ABSTRACT
A 39-year-old woman with systemic lupus erythematosus treated with anti-CD20 monoclonal antibody rituximab was admitted to our hospital with COVID-19 pneumonia. Despite receiving dexamethasone, she developed hypoxaemia and persistent lung opacities. As bronchoalveolar lavage was suggestive of cryptogenic organising pneumonia, high-dose corticosteroid was administered, and she received antimicrobial therapy for opportunistic infections without improvement. Reverse transcription PCR was repeatedly positive for SARS-CoV-2, and virus replication was confirmed in cell cultures. As no anti-SARS-CoV-2 antibodies were detected more than 100 days after symptom onset, she was treated with convalescent plasma with fast clinical improvement, returning home days later. Our case shows that persistent SARS-CoV-2 infection in an immunocompromised patient may be overturned with the appropriate treatment.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Lupus Erythematosus, Systemic
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Adult
/
Female
/
Humans
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Bcr-2021-244853
Similar
MEDLINE
...
LILACS
LIS